Summary

KEY FINDINGS
The global dry eye disease market is forecasted to record a CAGR of 5.11% during the projected period of 2023-2032. The market growth is ascribed to factors such as the launch of promising pipeline products for dry eye disease, the introduction of new diagnostic techniques for dry eye disease, and the increasing incidence of dry eye among different age groups.
MARKET INSIGHTS
Dry eye is a chronic syndrome, progressive depending on the severity and cause. It is a condition when a person does not have tears to lubricate their eyes. Tears are a vital part of maintaining good eye health and assist in ensuring good vision. The syndrome is typically witnessed among older people. However, it is also becoming common among people who spend long hours in front of the computer.
The accurate diagnosis of dry eye disease is pivotal. Whether it is a practice focusing on a subspecialty, such as glaucoma and retina, or a primary anterior segment practice, the symptoms and signs of dry eye disease are widespread across modern lifestyles. Technological advancements are being made in the field of ophthalmology. Leading firms operating in the market continually concentrate on developing novel therapeutics and diagnostics, as well. For instance, TearScience, a subsidiary of Johnson & Johnson, introduced the latest diagnostic system for dry eye disease in the market, named LipiView II Ocular Surface Interferometer.
REGIONAL INSIGHTS
The global dry eye disease market growth evaluation entails the assessment of the Asia-Pacific, Europe, North America, and the Rest of World. The Asia-Pacific is set to grow with the highest CAGR over the forecasting years due to the increasing number of ophthalmologists in countries like China, India, and Japan, providing good treatment and diagnostic services for ophthalmic conditions and the growing ophthalmic education.
COMPETITIVE INSIGHTS
Significant competition exists between key market players for the development of a new treatment for dry eye disease. The highly sustainable competitive advantages through innovation are likely to intensify rivalry among firms. Besides, solid strategies are anticipated to raise the competition in the market studied.
Some of the top companies operating in the market are Johnson & Johnson, Allergan PLC (Acquired by Abbvie), Bausch Health Companies Inc, etc.

ページTOPに戻る

Table of Contents

TABLE OF CONTENTS
1. RESEARCH SCOPE & METHODOLOGY
1.1. STUDY OBJECTIVES
1.2. METHODOLOGY
1.3. ASSUMPTIONS & LIMITATIONS
2. EXECUTIVE SUMMARY
2.1. MARKET SIZE & ESTIMATES
2.2. MARKET OVERVIEW
2.3. SCOPE OF STUDY
2.4. CRISIS SCENARIO ANALYSIS
2.5. MAJOR MARKET FINDINGS
2.5.1. AIR POLLUTION IS A MAJOR CAUSE OF EYE DISEASES
2.5.2. COVID-19 CONTRIBUTED TO A HIGH NUMBER OF DRY EYE DISEASE CASES
2.5.3. ASIAN RACE IS AT HIGHER RISK OF DEVELOPING DRY EYE DISEASE
2.5.4. EXCESSIVE SCREEN TIME CAN INDUCE DRY EYE SYMPTOMS
3. MARKET DYNAMICS
3.1. KEY DRIVERS
3.1.1. INTRODUCTION OF NOVEL DIAGNOSTIC TECHNIQUES FOR DRY EYE DISEASE
3.1.2. LAUNCH OF PROMISING PIPELINE PRODUCTS FOR DRY EYE DISEASE
3.1.3. GROWING INCIDENCE AND PREVALENCE OF DRY EYE AMONG DIFFERENT AGE GROUPS
3.2. KEY RESTRAINTS
3.2.1. RISK OF SIDE EFFECTS
3.2.2. SUBSTITUTE THERAPIES
3.2.3. EXPENSIVE SPECIALTY PRODUCTS AND COMPLEX REIMBURSEMENT SCENARIO
4. KEY ANALYTICS
4.1. PARENT MARKET ANALYSIS
4.2. KEY MARKET TRENDS
4.3. PORTER’S FIVE FORCES ANALYSIS
4.3.1. BUYERS POWER
4.3.2. SUPPLIERS POWER
4.3.3. SUBSTITUTION
4.3.4. NEW ENTRANTS
4.3.5. INDUSTRY RIVALRY
4.4. GROWTH PROSPECT MAPPING
4.5. MARKET MATURITY ANALYSIS
4.6. MARKET CONCENTRATION ANALYSIS
4.7. VALUE CHAIN ANALYSIS
4.7.1. RESEARCH AND DEVELOPMENT
4.7.2. MANUFACTURING
4.7.3. DISTRIBUTORS
4.7.4. POST-SALES MONITORING
5. MARKET BY TYPE
5.1. OTC
5.2. PRESCRIPTION
6. MARKET BY PRODUCT
6.1. ANTI-INFLAMMATORY DRUGS
6.1.1. CYCLOSPORINE
6.1.2. CORTICOSTEROID
6.1.3. OTHER ANTI-INFLAMMATORY DRUGS
6.2. ARTIFICIAL TEARS
6.3. PUNCTAL PLUGS
6.4. SECRETAGOGUES
6.5. OTHER PRODUCTS
7. MARKET BY DISTRIBUTION CHANNEL
7.1. HOSPITAL PHARMACIES
7.2. INDEPENDENT PHARMACIES AND DRUGSTORES
7.3. ONLINE PHARMACIES
8. GEOGRAPHICAL ANALYSIS
8.1. NORTH AMERICA
8.1.1. MARKET SIZE & ESTIMATES
8.1.2. NORTH AMERICA DRY EYE DISEASE MARKET DRIVERS
8.1.3. NORTH AMERICA DRY EYE DISEASE MARKET CHALLENGES
8.1.4. NORTH AMERICA DRY EYE DISEASE MARKET REGULATORY FRAMEWORK
8.1.5. KEY PLAYERS IN NORTH AMERICA DRY EYE DISEASE MARKET
8.1.6. COUNTRY ANALYSIS
8.1.6.1. UNITED STATES
8.1.6.1.1. UNITED STATES DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
8.1.6.2. CANADA
8.1.6.2.1. CANADA DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
8.2. EUROPE
8.2.1. MARKET SIZE & ESTIMATES
8.2.2. EUROPE DRY EYE DISEASE MARKET DRIVERS
8.2.3. EUROPE DRY EYE DISEASE MARKET CHALLENGES
8.2.4. EUROPE DRY EYE DISEASE MARKET REGULATORY FRAMEWORK
8.2.5. KEY PLAYERS IN EUROPE DRY EYE DISEASE MARKET
8.2.6. COUNTRY ANALYSIS
8.2.6.1. UNITED KINGDOM
8.2.6.1.1. UNITED KINGDOM DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
8.2.6.2. GERMANY
8.2.6.2.1. GERMANY DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
8.2.6.3. FRANCE
8.2.6.3.1. FRANCE DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
8.2.6.4. ITALY
8.2.6.4.1. ITALY DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
8.2.6.5. BELGIUM
8.2.6.5.1. BELGIUM DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
8.2.6.6. SPAIN
8.2.6.6.1. SPAIN DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
8.2.6.7. POLAND
8.2.6.7.1. POLAND DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
8.2.6.8. REST OF EUROPE
8.2.6.8.1. REST OF EUROPE DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
8.3. ASIA-PACIFIC
8.3.1. MARKET SIZE & ESTIMATES
8.3.2. ASIA-PACIFIC DRY EYE DISEASE MARKET DRIVERS
8.3.3. ASIA-PACIFIC DRY EYE DISEASE MARKET CHALLENGES
8.3.4. ASIA-PACIFIC DRY EYE DISEASE MARKET REGULATORY FRAMEWORK
8.3.5. KEY PLAYERS IN ASIA-PACIFIC DRY EYE DISEASE MARKET
8.3.6. COUNTRY ANALYSIS
8.3.6.1. CHINA
8.3.6.1.1. CHINA DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
8.3.6.2. JAPAN
8.3.6.2.1. JAPAN DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
8.3.6.3. INDIA
8.3.6.3.1. INDIA DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
8.3.6.4. SOUTH KOREA
8.3.6.4.1. SOUTH KOREA DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
8.3.6.5. INDONESIA
8.3.6.5.1. INDONESIA DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
8.3.6.6. THAILAND
8.3.6.6.1. THAILAND DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
8.3.6.7. AUSTRALIA & NEW ZEALAND
8.3.6.7.1. AUSTRALIA & NEW ZEALAND DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
8.3.6.8. REST OF ASIA-PACIFIC
8.3.6.8.1. REST OF ASIA-PACIFIC DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
8.4. REST OF WORLD
8.4.1. MARKET SIZE & ESTIMATES
8.4.2. REST OF WORLD DRY EYE DISEASE MARKET DRIVERS
8.4.3. REST OF WORLD DRY EYE DISEASE MARKET CHALLENGES
8.4.4. REST OF WORLD DRY EYE DISEASE MARKET REGULATORY FRAMEWORK
8.4.5. KEY PLAYERS IN REST OF WORLD DRY EYE DISEASE MARKET
8.4.6. REGIONAL ANALYSIS
8.4.6.1. LATIN AMERICA
8.4.6.1.1. LATIN AMERICA DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
8.4.6.2. MIDDLE EAST AND AFRICA
8.4.6.2.1. MIDDLE EAST AND AFRICA DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
9. COMPETITIVE LANDSCAPE
9.1. KEY STRATEGIC DEVELOPMENTS
9.1.1. MERGERS & ACQUISITIONS
9.1.2. PRODUCT LAUNCHES & DEVELOPMENTS
9.1.3. PARTNERSHIPS & AGREEMENTS
9.1.4. BUSINESS EXPANSIONS & DIVESTITURES
9.2. COMPANY PROFILES
9.2.1. AFT PHARMACEUTICALS
9.2.2. ALCON
9.2.3. ALLERGAN PLC (ACQUIRED BY ABBVIE)
9.2.4. BAUSCH HEALTH COMPANIES INC
9.2.5. JOHNSON & JOHNSON
9.2.6. LUMENIS
9.2.7. NOVALIQ GMBH
9.2.8. NOVARTIS AG
9.2.9. OASIS MEDICAL
9.2.10. OTSUKA PHARMACEUTICAL CO LTD
9.2.11. SANTEN PHARMACEUTICAL CO LTD
9.2.12. SENTISS PHARMA PRIVATE LIMITED
9.2.13. SUN PHARMACEUTICAL INDUSTRIES LTD
9.2.14. TEVA PHARMACEUTICAL INDUSTRIES LTD
9.2.15. VISUFARMA